Macomics secures £3.2m in seed financing from Epidarex Capital and the Scottish Investment Bank to develop cancer immunotherapies
Epidarex Capital led the seed round to help the Edinburgh spin-out advance its tumour-associated macrophage platform.
Macomics is an immuno-oncology company specialising in macrophage biology to create first-in-class cancer therapeutics. The business builds on academic research from the University of Edinburgh to target tumour associated macrophages.
Macomics has secured £3.2m in seed funding led by Epidarex Capital, alongside participation from the Scottish Investment Bank. The spin-out from the University of Edinburgh will direct the capital towards advancing its proprietary target discovery platform and developing novel immunotherapies designed to modulate tumour-associated macrophages. In conjunction with the financing round, the company has appointed Robert Haigh as chief executive and Jane Dancer as a non-executive director to guide its next phase of growth.
From the founder
"Decades of research into macrophage biology, particularly that of tumour-associated macrophages, have made it very clear to me that this is an area of significant untapped potential for the development of novel cancer therapeutics. The creation of Macomics based on the research of my group at the University of Edinburgh provides the team with an exciting opportunity to develop new effective cancer drugs against macrophage targets, that will bring real clinical benefit to many more patients suffering from cancer."
Jeffrey Pollard
Director of the MRC Centre for Reproductive Health at the University of Edinburgh at Macomics
Investor perspective
"This is an extremely exciting immuno-oncology spin-out based on outstanding academic research. We are thrilled to support it alongside Epidarex Capital."
Kerry Sharp
Director, Scottish Investment Bank
Use of funds
- 01Continue product development
- 02Fund research and development
